Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 3, Issue 1

February 2026

In Progress

Blood Neoplasia Cover Image for Volume 3, Issue 1

In this Issue

CLINICAL TRIALS AND OBSERVATIONS
MYELOID NEOPLASIA
RESEARCH LETTER
TRANSLATIONAL RESEARCH
Lymphoid Neoplasia
BASIC MECHANISMS OF NEOPLASIA

Volume 3 Issue 1 | Blood Neoplasia | American Society of Hematology

CLINICAL TRIALS AND OBSERVATIONS

Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML
Clinical Trials & Observations

Jayanshu Jain,Kelly Pugh,Shivani Handa,Kaitlyn M. Dvorak-Kornaus,Qiuhong Zhao,Roland B. Walter,Rachel Cook,Jennifer Saultz,Ronan Swords,Junyang Li,George S. Laszlo,Nicole R. Grieselhuber,Alice S. Mims,Karilyn T. M. Larkin,Kieran Sahasrabudhe,James S. Blachly,Gregory K. Behbehani,Ann-Kathrin Eisfeld,Meixiao Long,Andrew Srisuwananukorn,Kristin L. Koenig,Uma Borate

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia
Clinical Trials & Observations

Tapan M. Kadia,Akhil Jain,Caitlin R. Rausch,Alex Bataller,Farhad Ravandi,Elias Jabbour,Wei Qiao,Gautam Borthakur,Nicholas Short,Guillermo Montalban-Bravo,Andres E. Quesada,Jan Burger,Alessandra Ferrajoli,William Wierda,Chitra Hosing,Hagop Kantarjian

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas
Clinical Trials & Observations

Julio C. Chavez,Ellen Napier,Attilio Bondanza,Andrew Lewandowski,Jennifer Mataraza,David Quinn,Paul Kwon,Frederick L. Locke,Boris Engels,Rakesh Awasthi,Petrina Georgala,Malgorzata Leyk,David Hynds,Michele Moschetta,Stephen J. Schuster

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

MYELOID NEOPLASIA

Targeting dysregulated epigenetic and transcription factor networks in KMT2A-rearranged AML using iPSC models

Anna Palau,Jonas Thier,Aonghus Naughton,Andrew Tae-Jun Kwon,David Cabrerizo Granados,Sophia Hofmann,Bogumił Kaczkowski,Xiangfu Zhong,Sören Lehmann,Erik Arner,Vanessa Lundin,Andreas Lennartsson

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Extended long-term follow-up and the survival of Stop Imatinib study

François-Xavier Mahon,Stéphanie Dulucq,Delphine Réa,Franck-Emmanuel Nicolini,Françoise Rigal-Huguet,Katerina Machova Polakova,Viviane Dubruille,Marie-Pierre Noel,Jean-Christophe Ianotto,Bruno Villemagne,Émilie Cayssials,Sophie Park,Philippe Rousselot,Gabriel Etienne

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial

Giovanni Martinelli,Scott R. Solomon,Sudipto Mukherjee,Armando Santoro,Stephen A. Strickland,Susana Vives,Farhad Ravandi,Roland B. Walter,Rachel J. Cook,Ewa Lech-Maranda,Maria Calbacho,Agnieszka Wierzbowska,Giovanni Marconi,Evelyn Acuña-Cruz,Isabel Cano-Ferri,Francesco Bertolini,Tomasz Rzymski,Alessandro Paoli,Giovanni Marino Merlo,Faten Koraichi Auriol,Sonia Zicari,Antonio Galleu,Ira Gupta,Pau Montesinos

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Impact of European LeukemiaNet–guided postremission therapy on outcomes of patients with AML from 2010 to 2022

Andrew F. Berdel,Julian Ronnacker,Daniela V. Wenge,Lina J. Kolloch,Philipp Berning,Linus Angenendt,Tobias J. Brix,Annette Westermann,Klaus Wethmar,Torsten Kessler,Andrea Kerkhoff,Rolf M. Mesters,Christian Reicherts,Jan-Henrik Mikesch,Wolfgang E. Berdel,Georg Lenz,Christoph Schliemann,Matthias Stelljes

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors

Alex C. H. Liu,Severine Cathelin,Dhanoop Manikoth Ayyathan,Yitong Yang,Farzaneh Aboualizadeh,Amina Abow,Gurbaksh Basi,Lance Li,David L. Dai,Abdula Maher,Eric Grignano,Mohsen Hosseini,Vivian Wang,Troy Ketela,Brandon Nicolay,Dylan M. Marchione,Adriana E. Tron,Andrea Arruda,Mark D. Minden,Steven M. Chan

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Adapted physical activity for hematology inpatients: focus on lean mass gain

Axel Sudria,Michael Loschi,Andrea Pinto,Laura Crousse,Sami Benachour,Rinzine Sammut,Frederic Chorin,Nicolas Mounier,Thomas Cluzeau

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

RESEARCH LETTER

Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade

Reid W. Merryman,Justin Kline,Robert A. Redd,Harrison Olszewski,Emma Welsh,Kathleen Pfaff,Hannah Lee,Mikaela McDonough,Inhye E. Ahn,Jennifer R. Brown,Jennifer L. Crombie,Matthew S. Davids,David C. Fisher,Eric D. Jacobsen,Caron A. Jacobson,Austin I. Kim,Oreofe O. Odejide,Erin Michelle Parry,Christine E. Ryan,Margaret A. Shipp,Philippe Armand,Scott Rodig,Jeremy S. Abramson,Ann S. LaCasce

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

TRANSLATIONAL RESEARCH

Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response

Anna Maria Corsale,Mojtaba Shekarkar Azgomi,Emilia Gigliotta,Marta Di Simone,Paola Pacelli,Francesca Cioffi,Elena Bestoso,Donatella Raspadori,Alessandro Gozzetti,Antonio Solimando,Paula Tabares,Andreas Beilhack,Maria Speciale,Giusy Corsale,Miriam Sciortino,Cristina Aquilina,Fulvio Brucato,Michele Cea,Renato Zambello,Francesca Garofano,Marta Biondo,Francesca Buffa,Nadia Caccamo,Francesco Dieli,Serena Meraviglia,Sergio Siragusa,Cirino Botta

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Lymphoid Neoplasia

Ratios of CD8 T lymphocytes to M-MDSCs (CD8MMR) predict prognosis in patients with untreated DLBCL

Hao-Yuan Wang,Fu-Chen Yang,Ching-Fen Yang,Chun-Kuang Tsai,Po-Chun Liu,Po-Shen Ko,Yao-Chung Liu,Jyh-Pyng Gau,Jin-Hwang Liu,Po-Min Chen,Nien-Jung Chen

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

BASIC MECHANISMS OF NEOPLASIA

SKIDA1 sustains MLL::ENL-expressing hematopoietic progenitors during neonatal stages and promotes B-lineage priming

Jonny Mendoza-Castrejon,Wei Yang,Elisabeth Denby,Rohini Muthukumar,Emily B. Casey,Riddhi M. Patel,Sarah K. Tasian,Jeffrey A. Magee

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

All Issues

Advertisement intended for health care professionals

Issue Archive

Volume 3 Issue 1 | Blood Neoplasia | American Society of Hematology

CLINICAL TRIALS AND OBSERVATIONS

Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML Clinical Trials & Observations

Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia Clinical Trials & Observations

Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas Clinical Trials & Observations

MYELOID NEOPLASIA

RESEARCH LETTER

TRANSLATIONAL RESEARCH

Lymphoid Neoplasia

BASIC MECHANISMS OF NEOPLASIA

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML
Clinical Trials & Observations

Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia
Clinical Trials & Observations

Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas
Clinical Trials & Observations